- Fusion Pharmaceuticals press release ( NASDAQ: FUSN ): Q3 GAAP EPS of -$0.55 misses by $0.04 .
- Revenue of $0.17M (-46.9% Y/Y) beats by $0.07M .
- As of September 30, 2022, Fusion held cash, cash equivalents and investments of $205.5 million, compared to cash, cash equivalents and investments of $220.8 million as of December 31, 2021. Fusion expects its existing cash, cash equivalents and investments as of September 30, 2022, will be sufficient to fund operations into the third quarter of 2024.
For further details see:
Fusion Pharmaceuticals GAAP EPS of -$0.55 misses by $0.04, revenue of $0.17M beats by $0.07M